J. Goldman & Co’s VanEck Pharmaceutical ETF PPH Stock Holding History

J. Goldman & Co’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.53M	Buy	+53,200	New	+$5.67M	0.16%	169
2025 Q4	–	Sell	-165,100	Closed	-$14.9M	–	696
2025 Q3	$14.9M	Buy	165,100 +33,300	+25%	+$2.92M	0.37%	77
2025 Q2	$11.6M	Sell	131,800 -55,000	-29%	-$4.77M	0.28%	117
2025 Q1	$17M	Buy	+186,800	New	+$16.8M	0.42%	79
2024 Q3	–	Sell	-35,000	Closed	-$3.2M	–	584
2024 Q2	$3.2M	Buy	+35,000	New	+$3.12M	0.09%	208
2024 Q1	–	Sell	-37,500	Closed	-$3.05M	–	501
2023 Q4	$3.05M	Buy	+37,500	New	+$2.94M	0.12%	160
2021 Q2	–	Sell	-45,000	Closed	-$3.1M	–	489
2021 Q1	$3.1M	Sell	45,000 -21,800	-33%	-$1.5M	0.1%	210
2020 Q4	$4.44M	Sell	66,800 -24,700	-27%	-$1.58M	0.23%	121
2020 Q3	$5.69M	Buy	+91,500	New	+$5.79M	0.39%	86

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

J. Goldman & Co's PPH Position: Q4 2025 in Review

J. Goldman & Co sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2025, closing a stake of 67,015 shares — an estimated $6.06M sold.

J. Goldman & Co first reported a position in PPH in Q3 2025 and held it in 1 quarter. The position peaked at $6.06M in Q3 2025. 146 funds tracked by Wall St. Rank hold PPH as of Q4 2025.

J. Goldman & Co reported no remaining VanEck Pharmaceutical ETF position as of Q4 2025 after selling out during the quarter.
J. Goldman & Co sold 67,015 VanEck Pharmaceutical ETF shares in Q4 2025, an estimated $6.06M.
J. Goldman & Co first reported a position in VanEck Pharmaceutical ETF in Q3 2025 and held it in 1 quarter.
J. Goldman & Co's VanEck Pharmaceutical ETF position peaked at $6.06M in Q3 2025.
146 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.